New guidance issued by the National Institute for Health and Care Excellence (NICE) recommends a significant expansion in the availability of continuous glucose monitoring (CGM) and Flash glucose monitoring for individuals living with diabetes. This update, welcomed by organisations like Diabetes UK, could transform how thousands of people manage their condition, potentially leading to better health outcomes and a reduced burden on NHS services.
Flash and CGM technologies allow users to monitor their glucose levels continuously throughout the day and night without the need for frequent finger-prick tests. Flash monitoring involves scanning a sensor worn on the arm, while CGM devices transmit data automatically to a smartphone or receiver. Both provide real-time insights into glucose trends, helping individuals and their healthcare teams make more informed decisions about diet, exercise, and medication, thereby preventing dangerous highs and lows.
The previous NICE guidelines restricted access to these advanced monitoring systems to specific groups, often those with complex needs or recurrent hypoglycaemia. The revised recommendations propose broadening this access considerably, extending eligibility to more people with type 1 diabetes and, crucially, to a wider cohort of individuals with type 2 diabetes who use insulin. This shift reflects growing evidence of the benefits of these technologies in improving glycaemic control and quality of life.
Diabetes is a chronic condition affecting millions in the UK. According to Diabetes UK, over 5 million people are currently living with diabetes in the UK, with around 90% having type 2 diabetes. Poorly managed diabetes can lead to severe long-term complications, including heart disease, stroke, kidney failure, nerve damage, and blindness, placing considerable strain on the NHS. By enabling better self-management, these technologies are anticipated to reduce such complications and associated hospital admissions.
While the NICE guidelines provide national recommendations, their implementation will ultimately depend on local NHS integrated care boards (ICBs) and clinical commissioning groups (CCGs). These bodies will be responsible for allocating resources and ensuring that eligible patients can access the technology. The move is expected to be cost-effective in the long run, as the initial investment in devices could be offset by reductions in emergency care and the treatment of diabetes-related complications.
Organisations supporting people with diabetes have long campaigned for wider access to these technologies, citing their potential to empower individuals and improve daily management of the condition. The new guidance represents a significant step forward in making these tools available to a much larger proportion of the diabetes community across the country.